NASDAQ: GOVX

Addressing Critical Unmet Medical Needs and Large Commercial Opportunities

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing infectious disease vaccines and solid tumor immunotherapies using novel proprietary platforms.

Mission Driven

Addressing infectious diseases, solid tumor cancers and biosecurity priorities.

High-Value Pipeline

GeoVax's pipeline is led by GEO-MVA, a Mpox/smallpox vaccine prioritized on an expedited pathway to commercialization for urgent public-health and biodefense needs. Also, additional upside exists from solid tumor cancer therapies and other infectious disease vaccines.

Biosecurity Alignment

Strengthening U.S. biodefense & global health security; reducing foreign dependency.

Media Contact:
Jessica Starman
media@geovax.com

Partnership Contact:
John Sharkey, PhD
VP, Business Development
jsharkey@geovax.com

www.geovax.com

Near term clinical development milestones in Mpox/smallpox vaccine and Head & Neck Cancer Therapy

Investment Highlights

- **Experienced Team:** Proven track record in delivering significant shareholder value (Leadership Team)
- **Regulatory Expedited Pipeline:** Pivotal Ph 3 GEO-MVA data readout anticipated mid-2027
- **Strong IP Estate:** Over 130 patents across 22 different families
- **Large Unmet Needs:** Significant global supply gap in Mpox/smallpox vaccines, with rising demand exceeding available manufacturing capacity

Lead Clinical Programs

- **GEO-MVA:** Mpox/smallpox vaccine with ***expedited clinical pathway positioned for commercialization and revenue generation.***
- **Gedeptin®:** Tumor agnostic cancer immunotherapy with FDA Orphan Drug designation preparing for Ph 2 trial combined with ICI in 1st line head & neck cancer

Upcoming Milestone Catalysts

- **Q4 '26:** GEO-MVA Mpox/smallpox clinical trial initiation – data readout mid-2027; expedited pathway to commercialization
- **H2 '27:** Ph 2 trial in 1st line HNC:; Gedeptin + Immune Checkpoint Inhibitor initiation

Market Potential Addressing Unmet Medical Needs



Advancing a Novel Pipeline in High-Value Areas

Product	Initial Target	Development Stage
GEO-MVA	Mpox/Smallpox	Pivotal Ph 3 initiating Q4 ‘26
Gedeptin®	Head & Neck Cancer	Ph 2 initiating H2 ‘27

Modified Vaccinia Ankara (MVA) Platform

MVA is a viral vector vaccine platform that uses a safe/harmless virus as a delivery vehicle delivering instructions into cells to trigger immunity to fight pathogens (viruses). MVA features include:



- **Exceptionally Safe:** does not replicate in humans
- **Special Populations:** proven to be safe including among patients with weakened immune systems, pregnant women and children
- **Provides Durable (Long Lasting) & Broad Immunity:** induces both antibodies and T-cell immunity, potentially providing longer effectiveness including against new viral variants
- **Multi-Antigenic:** can address multiple diseases in same vaccine
- **Thermal Stability:** doesn’t require ultra-cold storage

Gedeptin® “Tumor Agnostic” Technology

Tumor-Targeted Gene Delivery
A therapeutic gene is delivered directly into tumor cells.
Localized, intratumoral administration

→

Enzyme Expressed Only in Tumor
Tumor cells begin producing a foreign enzyme not found in healthy tissue.

→

Prodrug Activated Inside Tumor
A systemically administered prodrug is converted into a potent toxin only inside the tumor.

→

Cancer Cell Death + Bystander Effect
Activated drug kills treated cancer cells and neighboring tumor cells.

- **Tumor-Selective Activation only in gene-expressing tumor cells**
- **Platform-Agnostic Application across multiple solid tumors**
- **Human Clinical Phase1/2 evidence of tumor-killing activity**
- **Combination optionality with Immune Checkpoint Inhibitors**

Tumor-selective gene therapy evaluated in solid tumors, with potential applicability across indications and in combination regimens